CCEL / Cryo-Cell International, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2026 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commiss

CRYO-CELL RECEIVES ACCEPTANCE OF COMPLIANCE PLAN FROM NYSE AMERICAN

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL RECEIVES ACCEPTANCE OF COMPLIANCE PLAN FROM NYSE AMERICAN OLDSMAR, FL. – May 8, 2026 – Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American

Revenue Recognition

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2026 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT

CRYO-CELL RECEIVES NYSE AMERICAN CONTINUED LISTING NOTICE

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL RECEIVES NYSE AMERICAN CONTINUED LISTING NOTICE OLDSMAR, FL. – March 12, 2026 – Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”)

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2026 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi

DESCRIPTION OF SECURITIES

Exhibit 4.1 DESCRIPTION OF SECURITIES The following descriptions of the common stock of Cryo-Cell International, Inc., or the Company, Delaware law and certain provisions of the Company’s certificate of incorporation and bylaws are summaries. These summaries are qualified in the entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of t

Revenue Recognition NOTES TO CONSOLIDATED FINANCIAL STATEMENTS November 30, 2025 and 2024

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

CRYO-CELL INTERNATIONAL, INC. INSIDER TRADING POLICY

Exhibit 19.1 CRYO-CELL INTERNATIONAL, INC. INSIDER TRADING POLICY 1. PURPOSE This Insider Trading Policy (the “Policy”) is designed to promote compliance with U.S. securities laws and prevent insider trading on the basis of material nonpublic information (“MNPI”). Unlawful insider trading occurs when a person uses MNPI obtained through employment or other involvement with a company to make decisio

Code of Business Conduct & Ethics

Exhibit 14 Code of Business Conduct & Ethics Cryo-Cell International, Inc. (the “Company”) is committed to the highest level of ethical behavior and the Company's business success depends upon the reputation of the Company and its directors, officers and employees to perform with the highest level of integrity and principled business conduct. This Code of Business Conduct and Ethics (the “Code”) a

“Maturity Date” means (a) with respect to the Revolving Credit Facility, October 18, 2027, or such earlier date on which the Revolving Credit Commitment of each Revolving Credit Lender terminates as provided in this Agreement, and (b) with respect

Exhibit 10.69 FIFTH AMENDMENT TO CREDIT AGREEMENT THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed to be effective as of October 18, 2025, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), Celle Corp., a Delaware corporation (“New Guarantor”), SUSSER BANK, a Texas State Bank, as administrative agent (“Administrative Agent”), and each of the Lenders

Subsidiaries of Cryo-Cell International, Inc.

Exhibit 21 Subsidiaries of Cryo-Cell International, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Celle Corp. Delaware

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

SEVENTH LEASE AMENDMENT

SEVENTH LEASE AMENDMENT THIS LEASE AMENDMENT dated July 8, 2025 by and between CRYO-CELL INTERNATIONAL, INC.

Revenue Recognition

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO

PROXY STATEMENT PROPOSAL 1 - ELECTION OF DIRECTORS PROPOSAL 2 - RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS REPORT OF THE AUDIT COMMITTEE SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT EXECUTIVE AND DIRECTOR COMPENSATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta

ARS

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of r

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 08, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (C

Fourth Amendment to Credit Agreement

Exhibit 10.6 FOURTH AMENDMENT TO CREDIT AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed as of July 15, 2025, to be effective as of July 18, 2025, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), SUSSER BANK, a Texas State Bank, as administrative agent (“Administrative Agent”), and each of the Lenders party hereto. A. Borrower, Administr

Revenue Recognition

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commiss

CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND OLDSMAR, FL –May 8, 2025 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic env

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commiss

Revenue Recognition

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

As filed with the Securities and Exchange Commission on November 12, 2024

As filed with the Securities and Exchange Commission on November 12, 2024 Registration No.

Filing Fee Table

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Cryo-Cell International, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND OLDSMAR, FL – October 30, 2024 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that its

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2024 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1)

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (C

Commercial Lease

Exhibit 10.5 COMMERCIAL LEASE This Commercial Lease (this " Lease") is entered into as of the 1st day of July 2024 by and between Deborah Portnoy ("Lessor ") and Crvo-Cell International , Inc. ("Lessee "). WITNESSETH: That for and in consideration of the mutual covenants, promises and conditions contained herein, Lessor hereby lets, leases and devises to Lessee, and Lessee does hereby take and acc

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT

Master Services Agreement with Emmes Biopharma Services LLC

Exhibit 10.5 Master Services Agreement This Master Services Agreement (this “Agreement”) is entered into as of August 10, 2023 (the “Effective Date”), by and between Cryo-Cell International, Inc., (“Customer”) and Emmes Biopharma Services LLC and its Affiliates and Subsidiaries (“Emmes”), a Maryland limited liability company with its principal address in Maryland at 401 North Washington Street, Su

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi

CRYO-CELL ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVES AND SPIN-OFF CELLE CORP. TO MAXIMIZE SHAREHOLDER VALUE

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVES AND SPIN-OFF CELLE CORP. TO MAXIMIZE SHAREHOLDER VALUE OLDSMAR, FL. – March 25, 2024 – Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells

Third Amendment to Credit Agreement

EX-10.66 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed as of November 28, 2023 to be effective as of August 31, 2023, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), SUSSER BANK, a Texas State Bank, as administrative agent (“Administrative Agent”), and each of the Lenders party hereto. A. Borrower, Administra

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

Clawback Policy

EX-97 CRYO-CELL INTERNATIONAL, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Cryo-Cell International, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has, therefore,

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

ARS

U.S.SecuritiesandExchangeCommission Washington,D.C.20549 FORM10-K È ANNUALREPORTUNDERSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934. ForthefiscalyearendedNovember30,2022 ‘ TRANSITIONREPORTUNDERSECTION13OR15(d)OFTHESECURITIESEXCHANGEACT OF1934. Forthetransitionperiodfrom to CommissionFileNumber001-40767 CRYO-CELLINTERNATIONAL,INC. (ExactNameofregistrantasspecifiedinitscharter) DELAWARE 22-302309

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40767 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Per

NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40767 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: February 28, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi

Second Amendment to License Agreement

SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment, dated February 17, 2023 (“Effective Date”), is by and between Cryo-Cell International, Inc.

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 5)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2022 (Date of Ev

Cryo-Cell International, Inc.

Cryo-Cell International, Inc. WITHDRAWAL REQUEST VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 February 3, 2023 Re: Cryo-Cell International, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-264108 CIK No.: 0000862692 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

2022 Employment Agreement for David Portnoy

Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2022 EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2022 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and David Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Execut

2022 Employment Agreement for Mark Portnoy

EX-10.2 3 ccel-ex102.htm EX-10.2 Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. 2022 EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Employment Agreement (the “Agreement”) is effective as of December 1, 2022 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and Mark Portnoy (the “Executive”). Executive is currently employed as the Co-Chief Executive Officer of the Company,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: August 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO

Amendment to the Credit Agreement between Cryo-Cell International and Susser Bank

Exhibit 10.6 AMENDMENT TO CREDIT AGREEMENT THIS AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is executed to be effective as of July 29, 2022, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (?Borrower?), SUSSER BANK, a Texas State Bank, as administrative agent (?Administrative Agent?), and each of the Lenders party hereto. A. Borrower, Administrative Agent, and Lenders are party

Credit Agreement among Cryo-Cell International, Inc. and Susser Bank

Exhibit 10.5 CREDIT AGREEMENT among CRYO-CELL INTERNATIONAL, INC., as Borrower THE GUARANTORS FROM TIME TO TIME PARTY HERETO THE LENDERS FROM TIME TO TIME PARTY HERETO and SUSSER BANK, as Administrative Agent DATED AS OF July 18, 2022 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Accounting Matters. 32 Section 1.3 ERISA Matters 33 Section 1.4 Reserved 33 Sec

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 d310686ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40767 Cryo-Cell Internati

OMB APPROVAL OMB Number: 3235-0080 Expires: May 31, 2024 Estimated average burden hours per response 1.

NYSE AMERICAN CERTIFICATION

New York Stock Exchange 11 Wall Street New York, NY 10005 Tel: +1 212.656.3000 nyse.com August 29, 2022 Chief, Information Technology Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE MS 3040 Washington, DC 20549 To whom it may concern: The NYSE American certifies its approval for listing and registration of the Common Stock, $0.01 par value, of CRYO-CELL INTERNATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 22-3023093 (State of Incorporation or Organization) (IRS Employer Identification No.) 700 Brooker Creek

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commis

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL

Form of Notes (included as Exhibit A to Exhibit 4.2 above)

Exhibit 4.2 Cryo-Cell International, Inc. and U.S. Bank Trust Company, National Association, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of [May , 2022] to the Indenture dated as of [May , 2022] [ ]% Senior Notes due [20 ] TABLE OF CONTENTS Page ARTICLE 1 APPLICATION OF FIRST SUPPLEMENTAL INDENTURE 1 Section 1.01. Application of First Supplemental Indenture. 1 ARTICLE 2 DEFINITIONS 2 Section

Form of Underwriting Agreement

Exhibit 1.1 CRYO-CELL INTERNATIONAL, INC. 8.625% SENIOR NOTES DUE 2026 UNDERWRITING AGREEMENT [ ], 2022 Ladenburg Thalmann & Co. Inc. As representative of the several underwriters c/o Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Cryo-Cell International, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Unde

As filed with the Securities and Exchange Commission on April 27, 2022

Table of Contents As filed with the Securities and Exchange Commission on April 27, 2022 Registration No.

Form of Indenture

Exhibit 4.1 CRYO-CELL INTERNATIONAL, INC. TO U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION AS TRUSTEE INDENTURE DATED AS OF [ , 2022] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 8 Section 1.3 Form of Documents Delivered to Trustee. 9 Section 1.4 Acts of

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1)

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-4076

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT

2022 Equity Incentive Plan.

Exhibit 10.4 Cryo-Cell International, Inc. 2022 EQUITY INCENTIVE PLAN Article I PURPOSE The purpose of this Cryo-Cell International, Inc. 2022 Equity Incentive Plan (the ?Plan?) is to benefit Cryo-Cell International, Inc., a Delaware corporation (the ?Company?) and its stockholders, by assisting the Company and its subsidiaries to attract, retain and provide incentives to key management employees,

First Amendment to License Agreement with BioE LLC

EXHIBIT 10.60 FIRST AMENDMENT TO LICENSE AGREEMENT THIS FIRST AMENDMENT TO LICENSE AGREEMENT (the ?Amendment?), made this 12th day of July, 2017, by and among BioE LLC, a Minnesota limited liability company with offices located at 8000 Norman Center Drive, #620, Bloomington, MN 55437 (?Licensor?), CytoMedical Design Group LLC, a Minnesota limited liability, and Cryo-Cell International, Inc., a Del

Form T-1 Statement of Eligibility under Trust Indenture Act of 1938, as amended, of Trustee

Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Cryo-Cell International, Inc.

As filed with the Securities and Exchange Commission on April 4, 2022

Table of Contents As filed with the Securities and Exchange Commission on April 4, 2022 Registration No.

Credit Agreement with Texas Capital Bank dated May 20, 2016

Exhibit 10.43 CREDIT AGREEMENT between CRYO-CELL INTERNATIONAL, INC. and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION DATED AS OF May 20, 2016 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.1 Definitions 1 1.2 Accounting Matters 10 1.3 ERISA Matters 10 1.4 Other Definitional Provisions 10 ARTICLE 2 ADVANCES AND LETTERS OF CREDIT 10 2.1 Advance 10 2.2 General Provisions Regarding Interest; Etc. 11 2.

Exclusive License Agreement with BioE LLC

EXHIBIT 10.59 BIOE LICENSE AGREEMENT WITH CRYO-CELL INTERNATIONAL CORD BLOOD TECHNOLOGY EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this ?Agreement?), is entered into this 30th day of June, 2015 (the ?Effective Date?), by and among BioE LLC, a Minnesota limited liability company with offices located at 8000 Norman Center Drive, #620, Bloomington, MN 55437 (?Licensor?), Cytomedica

First Amendment to Credit Agreement with Texas Capital Bank.

Exhibit 10.44 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is executed to be effective as of August 26, 2016, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (?Borrower?) and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (?Lender?). A. Borrower and Lender are party to that certain Credit Agreement dated as

Services Agreement

EXHIBIT 10.61 SERVICES AGREEMENT BY AND BETWEEN CORD:USE Cord Blood Bank, Inc. AND DUKE UNIVERSITY THIS SERVICES AGREEMENT (?Agreement?) is entered into as of July 28, 2017 (?Effective Date?), by and between CORD:USE Cord Blood Bank, Inc., a Florida corporation (?CORD:USE?) and Duke University through its School of Medicine (?Duke?) (each a ?Party? and collectively the ?Parties?). RECITALS WHEREAS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi

CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL ? March 16, 2022 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announces it has entered into

Purchase Agreement between Scannell Properties #502, LLC and Cryo-Cell International, Inc. dated March 14, 2022

Exhibit 10.1 PURCHASE AGREEMENT BETWEEN SCANNELL PROPERTIES #502, llc AS SELLER AND CRYO-CELL INTERNATIONAL, INC. AS PURCHASER March 14, 2022 1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (?Agreement?) is made and entered into effective as of March 14, 2022 (the ?Effective Date?) by and among SCANNELL PROPERTIES #502, llc, an Indiana limited liability company (the ?Seller?) and CRYO-CELL INTERNATIO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. ? February 22, 2022 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announced results for its fis

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

First Amendment to License Agreement

Exhibit 10.59 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment, dated February 4, 2022, is by and between Cryo-Cell International, Inc. (?LICENSEE?) and Duke University ("DUKE"). WHEREAS, LICENSEE and DUKE entered into a license agreement dated February 23 2021 (the "License Agreement"); and WHEREAS, DUKE and LICENSEE desire to modify certain provisions of the License Agreement as provide

CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP Passive Investment

SC 13G/A 1 cryo13ga4-020421.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 4)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Numbe

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS

Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL ? October 15, 2021 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announced results f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 d142568ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (C

Cryo-Cell International Announces Changes To Its Board of Directors

? Exhibit 99.1 Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl, September 20, 2021 (GLOBENEWSWIRE) - Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company?s Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler,

CERT

The Nasdaq Stock Market LLC, 805 King Farm Blvd., Rockville, MD 20850 Eun Ah Choi Vice President, Listing Qualifications Deputy General Counsel August 30, 2021 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on August 27, 2021 The Nasdaq Stock Market LLC (the "Exchange") recei

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 22-3023093 (State of Incorporation or Organization) (IRS Employer Identification No.) 700 Brooker Creek

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissi

2021 Employment Agreement for Oleg Mikulinsky

Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2021 EMPLOYMENT AGREEMENT FOR OLEG MIKULINSKY This Employment Agreement (the ?Agreement?) is effective as of August 1, 2021 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Oleg Mikulinsky ( the ?Executive?). Executive is currently employed as the Chief Information Officer of the Company, and the Company and the Exec

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS

Exhibit 99.1 For Immediate ReleaseContact: Diane Glanz, Rph, PharmD Investor Relations Consultant 813-749-2195 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL ? July 15, 2021 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store st

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissi

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONAL,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commissi

2020 Employment Agreement for David Portnoy

Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2020 EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2020 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and David Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Execut

2020 Employment Agreement for Mark Portnoy

Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. 2020 EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2020 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Mark Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Executiv

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commiss

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS

Exhibit 99.1 For Immediate ReleaseContact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL – April 14, 2021 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord bloo

Quarterly Report - 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIO

Patent and License Technology Agreement

Exhibit 10.2 PATENT AND TECHNOLOGY LICENSE AGREEMENT DUKE UNIVERSITY AND CRYO-CELL INTERNATIONAL, INC. EFFECTIVE February 23, 2021 1 Table of Contents ARTICLE 1 - DEFINITIONS 3 ARTICLE 2 - GRANT OF LICENSE 7 ARTICLE 3 - CONSIDERATION 9 ARTICLE 4 - REPORTS 14 ARTICLE 5 - DILIGENCE 16 ARTICLE 6 - SUBLICENSING 19 ARTICLE 7 - PATENT APPLICATIONS AND MAINTENANCE 20 ARTICLE 8 - ENFORCEMENT 21 ARTICLE 9

Annual Report - 10-K

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020

Exhibit 99.1 For Immediate ReleaseContact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL. ? February 24, 2021 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992,

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Cryo-Cell In

SC 13G/A 1 cryo13ga3-021621.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Numbe

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commi

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020 FINANCIAL RESULTS

Exhibit 99.1 For Immediate ReleaseContact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells

Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Com

Quarterly Report - 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONA

Submission of Matters to a Vote of Security Holders - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation

LETTER

United States securities and exchange commission logo September 10, 2020 Jill M. Taymans Chief Financial Officer Cryo-Cell International, Inc. 700 Brooker Creek Blvd., Suite 1800 Oldsmar, FL 34677 Re: Cryo-Cell International, Inc. Form 10-K for the Fiscal Year Ended November 30, 2019 Filed February 28, 2020 File No. 000-23386 Dear Ms. Taymans: We have completed our review of your filings. We remin

-

United States securities and exchange commission logo September 10, 2020 Jill M. Taymans Chief Financial Officer Cryo-Cell International, Inc. 700 Brooker Creek Blvd., Suite 1800 Oldsmar, FL 34677 Re: Cryo-Cell International, Inc. Form 10-K for the Fiscal Year Ended November 30, 2019 Filed February 28, 2020 File No. 000-23386 Dear Ms. Taymans: We have completed our review of your filings. We remin

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, 8-K - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (

-

SEC Response Letter Bank of America Plaza 101 East Kennedy Boulevard Suite 2800 Tampa, Florida 33602 813.

- DEF 14A

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Shareholder Director Nominations

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Com

LETTER

United States securities and exchange commission logo July 13, 2020 Jill M. Taymans Chief Financial Officer Cryo-Cell International, Inc. 700 Brooker Creek Blvd., Suite 1800 Oldsmar, FL 34677 Re: Cryo-Cell International, Inc. Form 10-K for the Fiscal Year Ended November 30, 2019 Filed February 28, 2020 File No. 000-23386 Dear Ms. Taymans: We have limited our review of your filing to the financial

-

United States securities and exchange commission logo July 13, 2020 Jill M. Taymans Chief Financial Officer Cryo-Cell International, Inc. 700 Brooker Creek Blvd., Suite 1800 Oldsmar, FL 34677 Re: Cryo-Cell International, Inc. Form 10-K for the Fiscal Year Ended November 30, 2019 Filed February 28, 2020 File No. 000-23386 Dear Ms. Taymans: We have limited our review of your filing to the financial

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS OLDSMAR, FL – July 10, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

Quarterly Report - 10-Q

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CR

Patent Option Agreement

EX-10.1 Exhibit 10.1 PATENT OPTION AGREEMENT Duke University File(s) #4719, 5000, 5191, 5204, 6381, 6382, 6478, 6479, 6480, 6622, 6623, 6624, 6625 and 7094 This Patent Option Agreement (“Agreement”) is entered into on June 9, 2020 (“EFFECTIVE DATE”), between Duke University, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”) having the address in A

CORD BLOOD BANKING LEADER CRYO-CELL ENTERS INTO PATENT OPTION AGREEMENT WITH DUKE UNIVERSITY

EX-99.1 3 d943128dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ENTERS INTO PATENT OPTION AGREEMENT WITH DUKE UNIVERSITY OLDSMAR, FL – June 11, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s f

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (C

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS OLDSMAR, FL – April 14, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - 10-Q

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019 OLDSMAR, FL. – February 27, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells

CCEL / CRYO-CELL International, Inc. 10-K - Annual Report - 10-K

10-K 1 d807043d10k.htm 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CR

CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment

SC 13G/A 1 cryocell13ga2-123119.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Cla

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

Retrospective Amendments to the 2000 Stock Incentive Plan

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank t

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - 10-Q

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386

CCEL / CRYO-CELL International, Inc. PRE 14A - - PRE 14A

PRE 14A 1 d779709dpre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2019 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Co

Letter, dated October 2, 2019 from Wipfli to the Securities and Exchange Commission, regarding change in certifying accountant of the Company.

EX-16.1 2 d597710dex161.htm EX-16.1 Exhibit 16.1 October 2, 2019 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read CRYO CELL International, Inc.‘s statements included under Item 4.01 of its Form 8-K filed on October 2, 2019 and we agree with such statements concerning our firm. /s/ Wipfli LLP

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2019 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – July 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q

Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS

EX-99.1 2 d632379dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – April 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”)

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (C

CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report)

10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTER

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018

EX-99.1 2 d711858dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018 OLDSMAR, FL. – February 28, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to s

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CCEL / CRYO-CELL International, Inc. 10-K (Annual Report)

10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2018 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL,

CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP - FEBRUARY 14, 2019 Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.1)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2018 (Date of Eve

Amended and Restated By-Laws

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through December 6, 2018) ARTICLE I OFFICES The registered office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the Board of Director

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

8-K 1 d673855d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdi

CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018 RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018 RESULTS OLDSMAR, FL – October 15, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CCEL / CRYO-CELL International, Inc. FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-

Consent of Withium Smith & Brown, PC

EX-21.1 2 d611526dex211.htm EX-21.1 Exhibit 21.1 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We hereby consent to the incorporation by reference of our report on the December 31, 2017 and 2016 financial statements of Cord: Use Cord Blood Bank, Inc., dated May 29, 2018, included in this Current Report on Form 8-K/A, into the Registration Statement on Form S-8 (File No. 333-197483) of Cr

CORD:USE Cord Blood Bank, Inc. Financial Statements December 31, 2017 and 2016 With Independent Auditors’ Report

EX-99.1 Exhibit 99.1 CORD:USE Cord Blood Bank, Inc. Financial Statements December 31, 2017 and 2016 With Independent Auditors’ Report CORD:USE Cord Blood Bank, Inc. December 31, 2017 and 2016 TABLE OF CONTENTS Independent Auditors’ Report 1-2 Financial Statements Balance Sheets 3 Statements of Operations 4 Statements Shareholders’ Equity 5 Statements of Cash Flows 6 Notes to Financial Statements 7

Financial Statements and Exhibits

Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdict

CORD:USE Cord Blood Bank, Inc. BALANCE SHEETS (Unaudited) March 31, December 31, 2018 2017 ASSETS Current Assets Cash $ 555,214 $ 54,150 Accounts receivable (net of allowance for doubtful accounts of $26,000 and $21,000, respectively) 215,827 165,430

EX-99.2 Exhibit 99.2 CORD:USE Cord Blood Bank, Inc. BALANCE SHEETS (Unaudited) March 31, December 31, 2018 2017 ASSETS Current Assets Cash $ 555,214 $ 54,150 Accounts receivable (net of allowance for doubtful accounts of $26,000 and $21,000, respectively) 215,827 165,430 Inventory, net 15,898,037 15,786,457 Prepaid expenses and other current assets 183,476 291,053 Total current assets 16,852,554 1

Unaudited Pro Forma Combined Balance Sheet Cryo-Cell Cord:Use Net Cryo-Cell February 28, March 31, Pro Forma & Cord:Use 2018 2018 Adjustments (Pro Forma) ASSETS Current Assets Cash and cash equivalents $ 6,991,401 $ 555,214 $ (2,055,214 ) (a) $ 5,491

EX-99.3 Exhibit 99.3 Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) entered into an asset purchase agreement with Cord:Use Cord Blood Bank, Inc., (“Cord:Use”), pursuant to which the Company acquired certain assets from Cord:Use for total consideration of $14,000,000 on June 11, 2018 (“Acquisition”). The unaudited preliminary proforma condensed combined balance sheet as of February 28

Agreement between the Company and Messrs. Ellis and Sheehy

Exhibit 10.1 AGREEMENT This Agreement, dated as of August 13, 2018 (this “Agreement”), is by and among Brian Sheehy (“Sheehy”), Arthur Ellis (“Ellis”), and Cryo-Cell International, Inc. (the “Company”). NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are h

ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL’S BOARD OF DIRECTORS

EX-99.1 3 d603377dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL’S BOARD OF DIRECTORS OLDSMAR, FL – August 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first p

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporati

CCEL / CRYO-CELL International, Inc. DEF 14A

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS OLDSMAR, FL – July 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co

CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report)

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CR

CCEL / CRYO-CELL International, Inc. / Cu Blood, Inc. - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. ) CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) June 11, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to

Second Amended and Restated Promissory Note dated June 11, 2018

EX-2.3 3 d599145dex23.htm EX-2.3 Exhibit 2.3 SECOND AMENDED AND RESTATED PROMISSORY NOTE $15,499,999.81 June 11, 2018 FOR VALUE RECEIVED, CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), having an address at 700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL 34677, hereby promises to pay to the order of TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (toge

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commissi

Second Amendment to Credit Agreement with Texas Capital Bank dated June 11, 2018.

EX-2.2 Exhibit 2.2 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed to be effective as of June 11, 2018, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”) and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (“Lender”). A. Borrower and Lender are party to that certain Credit Agreement date

CRYO-CELL CONSUMMATES ACQUISITION OF CORD:USE ASSETS AND EXTENDS ITS LEADERSHIP POSITION INTO THE PUBLIC CORD BLOOD BANKING ARENA

EX-99.1 4 d599145dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL CONSUMMATES ACQUISITION OF CORD:USE ASSETS AND EXTENDS ITS LEADERSHIP POSITION INTO THE PUBLIC CORD BLOOD BANKING ARENA OLDSMAR, Fla. – June 15, 2018 – Cryo-Cell International, Inc. (OTC:QB

Asset Purchase Agreement, date May 29, 2018, between Cord:Use Cord Blood Bank, Inc. and Cryo-Cell International, Inc.

EX-2.1 2 d587398dex21.htm EX-2.1 Exhibit 2.1 Execution Copy ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of May 29, 2018, is entered into between Cord:Use Cord Blood Bank, Inc., a Florida corporation (“Seller”) and Cryo-Cell International, Inc., a Delaware corporation (“Buyer”). RECITALS WHEREAS, Seller is engaged in the business of public and private cord bl

CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK, INC.

EX-99.1 3 d587398dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK, INC. OLDSMAR, Fla. – June 4, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (

Amended Agreement with Oleg Mikulinsky effective December 1, 2017.

EX-10.1 2 d591479dex101.htm EX-10.1 Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement is entered into and effective as of December 1, 2017, by and between Cryo-Cell International, Inc. (the “Company”) and Oleg Mikulinsky (the “Executive”). RECITALS A. The Company and the Executive entered into an Employment Agreement dated March 5, 2012 (the “Employment Agreement”). B. The initial term of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2018 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissio

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS OLDSMAR, Fla. – April 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first privat

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report)

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233

Amended and restated Employment Agreement with Mark Portnoy dated March 8, 2018.

EX-10.2 Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made and is effective as of December 1, 2017 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and Mark Portnoy (“Executive”). WHEREAS, Executive is currently employed as the Co-Chief Exec

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2018 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm

Amended and restated Employment Agreement with David Portnoy dated March 8, 2018.

EX-10.1 2 d539529dex101.htm EX-10.1 Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made and is effective as of December 1, 2017 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and David Portnoy (“Executive”). WHEREAS, Executive is currently

Stockholder Agreement between Cryo-Cell International, Inc. and Mark Portnoy

EX-10.5 Exhibit 10.5 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and Mark L. Portnoy, is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and direct

Stockholder Agreement between Cryo-Cell International, Inc. and George Gaines

EX-10.3 Exhibit 10.3 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and George C. Gaines, Jr., is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and

Stockholder Agreement between Cryo-Cell International, Inc. and David Portnoy

Exhibit 10.4 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and David I. Portnoy, is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and directors red

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017

EX-99.1 2 d542982dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017 OLDSMAR, FL. – February 28, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to s

CCEL / CRYO-CELL International, Inc. 10-K (Annual Report)

10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2017 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL,

CBAI / Cord Blood America, Inc. / CRYO CELL INTERNATIONAL INC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 3 Under the Securities Exchange Act of 1934 Cord Blood America, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21839P206 (Cusip Number) Steven Lanter, Esq. Luse Gorman, PC 5335 Wisconsin Avenue, NW, Suite 780 Washington, D.C. 20015 (202) 274-20

CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP - FEBRUARY 14, 2018 Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2017 (Date of Even

CCEL / CRYO-CELL International, Inc. / Cdmj Nyberg Family Trust - SC 13G AMENDMENT NO. 4 Passive Investment

SC 13G Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the ap

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporat

CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017 RESULTS

Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017 RESULTS OLDSMAR, Fla. – October 16, 2017 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store st

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2017 FINANCIAL RESULTS

EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2017 FINANCIAL RESULTS OLDSMAR, Fla. ? July 7, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2017 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2017 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2017 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONAL,

CRYO-CELL International DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporatio

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017 FINANCIAL RESULTS

Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017 FINANCIAL RESULTS OLDSMAR, Fla. ? April 14, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first

CRYO-CELL International FORM 10-Q (Quarterly Report)

10-Q 1 d365977d10q.htm FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2017 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorpora

CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016

Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016 OLDSMAR, Fla. ? February 28, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announc

CCEL / CRYO-CELL International, Inc. 10-K - Annual Report - FORM 10-K

10-K 1 d272195d10k.htm FORM 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2016 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-233

CCEL / CRYO-CELL International, Inc. / Nyberg Charles Duane - SCHEDULE 13G AMENDMENT NO. 3 Passive Investment

Schedule 13G Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check

Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi

AMENDMENT TO RIGHTS AGREEMENT

EX-4.1 2 d285464dex41.htm AMENDMENT TO THE RIGHTS AGREEMENT Exhibit 4.1 AMENDMENT TO RIGHTS AGREEMENT Amendment to Rights Agreement (this “Amendment”), dated as of October, 31, 2016, between Cryo-Cell International, Inc., a Delaware corporation (the “Company”), and Continental Stock and Transfer Trust (the “Rights Agent”). Whereas, the Company entered into that certain Rights Agreement with the Ri

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q

Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2016 CRYO-CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporati

Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2016 CRYO-CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2016 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2016 FINANCIAL RESULTS

Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2016 FINANCIAL RESULTS OLDSMAR, Fla. ? July 11, 2016 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q

10-Q 1 d122646d10q.htm FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commi

Submission of Matters to a Vote of Security Holders

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (

Stock Purchase Agreement dated June 16, 2016.

Exhibit 2 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of the 16th day of June, 2016, by and between, on the one hand, Ki Yong Choi (?Choi?) and Michael Cho (?Cho? and, with Choi, collectively, ?Sellers?), and, on the other hand, Cryo-Cell International, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

CRYO-CELL International DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Amended and Restated By-Laws

Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through March 9, 2016) ARTICLE I OFFICERS The principal office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (

Amendment Agreement with Oleg Mikulinsky dated December 1, 2015.

EX-10.1 2 d174850dex101.htm EMPLOYMENT AGREEMENT BETWEEN CRYO-CELL INTERNATIONAL, INC. AND OLEG MIKULINSKY EXHIBIT 10.1 AMENDMENT AGREEMENT This Amendment Agreement is entered into and effective as of December 1, 2015, by and between Cryo-Cell International, Inc. (the “Company”) and Oleg Mikulinsky (the “Executive”). RECITALS A. The Company and the Executive entered into an Employment Agreement da

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 d174850d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2016 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdict

Amended and Restated Employment Agreement with David Portnoy dated December 1, 2015

Employment Agreement between Cryo-Cell International, Inc. and Mark Portnoy EXHIBIT 10.2 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Amended and Restated Employment Agreement (the ?Agreement?) is made as of December 1, 2015 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Mark Portnoy (?Executive?). WHEREAS, E

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2016 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation)

Amended and Restated Employment Agreement with David Portnoy dated December 1, 2015

EX-10.1 2 d132960dex101.htm EMPLOYMENT AGREEMENT BETWEEN CRYO-CELL INTERNATIONAL, INC. AND DAVID PORTNOY EXHIBIT 10.1 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made as of December 1, 2015 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and David Po

CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016 FINANCIAL RESULTS

Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016 FINANCIAL RESULTS OLDSMAR, Fla. ? April 14, 2016 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first

CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q

Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2016 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporatio